Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
Laura Z. Rassenti(University of California San Diego), Thomas J. Kipps(Moores Cancer Center), Donna Neuberg(Otsuka (Japan)), Feng He(University of California San Diego), Jennifer R. Brown(Dana-Farber Cancer Institute), Michael J. Keating(The University of Texas MD Anderson Cancer Center), Sonia Jain(University of Antwerp), Michael R. Grever(Johns Hopkins University), John G. Gribben(Queen Mary University of London), William G. Wierda(The University of Texas MD Anderson Cancer Center), John C. Byrd(The Ohio State University), Andrew Greaves(University of California San Diego), Neil E. Kay(Mayo Clinic)
Cited by 320
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k